Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis

Cancer Research

Volumn 56, Issue 20, 1996, Pages 4566-4569

  Reddy, Bandaru S ^a   Rao, Chinthalapally V ^a   Seibert, Karen ^b  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER RISK; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AZOXYMETHANE; CARCINOGENS; COLON; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG SCREENING ASSAYS, ANTITUMOR; ISOENZYMES; MALE; PRECANCEROUS CONDITIONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, INBRED F344; RATS, INBRED LEW; SULINDAC;

EID: 0029794742     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wingo, P A., Tong, T , and Bolden, S. Cancer statistics, 1995. CA Cancer J Clin., 45: 8-30, 1995.
2. Reddy, B. S. Diet and colon cancer, evidence from human and animal model studies In: B. S. Reddy and L A. Cohen (eds.), Diet, Nutrition and Cancer: A Critical Evaluation, pp 47-65, Boca Raton, FL: CRC Press, 1986.
3. Thun, M. H. Namboodiri, M M , Calle, E E., Flanders, W. D , and Heath, C. W. Aspirin use and reduced risk of fatal cancer. Cancer Res., 53: 1322-1327, 1993
4. Giovannucci, E., Timm, E. B., Stampfer, M. J., Colditz, G. A , Ascherio, A., and Willett, W. C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med., 121: 241-246, 1994.
5. Boolbol, S. K., Dannenberg, A J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J. T., Abreu-Goris, M , Newmark, H , Lipkin, M. L , DeCosse, J. J., and Bertagnolli, M. M Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial polyposis. Cancer Res., 50: 2556-2560, 1996.
6. Reddy, B. S., Rao, C. V., Rivenson, A , and Kelloff, G. J Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats Carcinogenesis (Lond), 14: 1493-1497, 1993.
7. Rao, C. V., Rivenson, A., Simi, B , Zang. E , Kelloff, G., Steele, V , and Reddy, B S Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55: 1464-1472, 1995.
8. Ahnen, D., Alberts, D., Hixson, L., Paranka, N., Burt, R., and Pamuku, R The sulfone metabolite of sulindac (FGN-1) inhibits rat colonic carcinogenesis but does not inhibit either prostaglandin synthesis or colonic proliferation Gastroenterology, 108: A444, 1995.
9. Giardiello, G. M., Hamilton, S. R , Krush, A. J., Piantodosi, S., Hylind, L M., Celano, P., Booker, S. V., Robinson, C. R. Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis N Engl. J. Med , 328: 1313-1316, 1993.
10. Mamett, L. J. Aspirin and the potential role of prostaglandins in colon cancer Cancer Res., 52: 5575-5589, 1992.
11. Rigas, B., Goldman, I. S., and Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122: 518-523, 1993.
12. Earnest, D. L , Hixson, L J., and Alberts, D. S Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J Cell. Biochem., 161 (Suppl): 156-166, 1992.
13. Piazza, G., Rahm, A., Pamuku, R., and Ahnen, D. Apoptosis fully accounts for the growth inhibitory activity of sulindac. Proc. Am Assoc. Cancer Res., 37, 279, 1996.
14. Kargman, S. L , O'Neill, G. P., Vickers, P. J., Evans, J F., Mancini, J. A., and Jothy, S. Expression of prostaglandin G/H syntheses-1 and -2 protein in human colon cancer. Cancer Res , 55 2556-2559, 1995.
15. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S, and DuBois, R. N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-1188, 1994.
16. DuBois, R. N , Radhika, A., Reddy, B. S., and Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology, 110: 1259-1262, 1996
17. Jones, D. A , Carlton, D P , McIntyre, T. M., Zimmerman, G A., and Prescott, S M. Molecular cloning of human prostaglandin endoperoxide synthases type II and demonstration of expression in response to cytokines J Biol. Chem., 268: 9049-9054, 1993
18. Seibert, K., Zhang, Y., Leahy, K , Hauser, S., Masferrer, J , Perkins, W., Lee, L , and Isakson, P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl Acad. Sci. USA, 91: 12013-12017, 1994.
19. Tsujii, M., and DuBois, R N Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthases-2. Cell, 83, 493-501, 1995.
20. Masferrer, J L., Zweifel, B. S., Manning, P T , Hauser, S D., Leahy, K. M., Smith, W G , Isakson, P. C., and Seibert, K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA, 91: 3228-3232, 1994
21. Meade, E A., Smith, W. L , and DeWitt, D L Differential inhibition of prostaglandin endoperoxide synthases (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem , 268: 6610-6614, 1993.
22. Deschner, E E. Experimentally induced cancer of the colon. Cancer (Phila.), 34: 824-828, 1974.
23. McLellan, E., Medline, A., and Bird, R P. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions Cancer Res., 51: 5270-5274, 1991.
24. Wargovich, M H , Chen, D-D., Jimenez, A., Steele, V. E , Velasco, M , Stephens, C., Price, R , Gray, K , and Kelloff, G. J. Aberrant crypts as a biomarker for colon cancer evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol , Biomarkers & Prev , 5: 355-360, 1996.
25. Rao, C. V., Desai, D., Simi, B., Kulkarni, N., Amin, S , and Reddy, B. S. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon Cancer Res., 53: 4182-4188, 1993.
26. Pretlow, T P , O'Riordan, M. A , Pretlow, T. G., and Stellato, T. A. Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J. Cell. Biochem., 16G (Suppl.): 55-62, 1992.
27. Vivona, A. A., Shpitz, B., Medline, A., Bruce, W R , Hay, K , Ward, M A. Stern, H. S., and Gallinger, S. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis (Lond.), 14 1777-1781, 1993.
28. Gierse, J. K., Hauser, S. D., Creely, D. P., Koboldt, C., Rangwala, S. H., Isakson, P. C , and Seibert, K Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J., 305, 479-484, 1995.
29. Jaffee, B. D. Kerr, J. S., Jones, E A., Giannaras, J. V., McGowan, M., and Ackerman, N R The effect of immunomodulating drugs on adjuvant-induced arthritis in Lewis rats. Agents Actions, 27: 344-346, 1989.
30. Battistini, B., Botting, R , and Bakhle, Y S. COX-1 and COX-2 toward the development of more selective NSAIDs Drug New Perspect , 7: 501-512, 1994
31. DeWitt, D L., Meade, W. A , and Smith, W L. PGH synthesis isozyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs Am. J. Med , 95 (Suppl.): 40S-44S, 1993.
32. Zhang, X-M., Stamp, D , Minkin, S , Medline, A., Corpet, D E., Bruce, W. R., and Archer, M. C. Promotion of aberrant crypt foci and cancer in rat colon by thermolyzed protein J. Natl. Cancer Inst , 84: 1026-1030, 1992
33. Pretlow, T. P., O'Riordan, M A , Somich, G. A., Amini, S B., and Pretlow, T. G. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis (Lond.), 13: 1509-1512, 1992.